Animal models for sleep disorders
Abstract
Introduction We spend a significant part (about a third) of our lives sleeping, which is essential to our physical and psychological well-being. Sleep, however, is a fragile state that can easily be impaired by psychological stress or physical illness. For up to 10% of the general population, difficulty falling and/or maintaining sleep occurs several times a week (i.e., chronic insomnia). Some of these problems may be due to existences of obstructive sleep apnea syndrome, a condition that affects over 10% of the population, or due to restless leg syndrome (RLS)/periodic leg movement syndrome (PLMS), sleep-related involuntary leg movements often associated with an abnormal sensation in legs. Excessive daytime sleepiness (EDS), parasomnia, and sleep problems associated with medical/psychiatric conditions are also common. Narcolepsy is a primary EDS disorder affecting about 0.05% of the population. EDS is also often secondary to a severe insomnia associated with obstructive sleep apnea. Many different pathophysiological/etiological mechanisms for these sleep disorders are considered, and the International Classification of Sleep Disorders (ICSD) lists over 84 different types of disorders (Table 29.1). These sleep-related problems are often chronic and negatively affect the subject's quality of life. In a 24-hr society that encourages sleep deprivation, daytime sleepiness is also an emerging issue even in healthy subjects. Accidents due to sleepiness are now well recognized as a…
How strong is the evidence?
Evidence Hub reads this as a book / chapter, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.